Oral atenolol for infantile hemangioma: case series of 46 infants

Calderón-Castrat, Ximena; Velásquez, Felipe; Castro, R.; Ballona, Rosalía

doi:10.1016/j.adengl.2019.11.004

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Other studies showed the effects of b1-selective blockers, like atenolol, in patients with infantile hemangioma, in which effective treatment was recorded in 61.8% to 89% of patients. 21,22 Our study showed that in infantile hemangiomas in the proliferating phase, non-selective betablockers, such as propranolol, are the first choice. If propranolol were to be replaced with b1-selective blockers, the possibility of a good response would have been 70% in infantile hemangioma in the proliferating phase.…”

Section: Discussionmentioning

confidence: 85%

Expression of β1 adrenergic receptor in vascular anomalies in children

et al. 2021

View full text Add to dashboard Cite

Objective Controversial, heterogeneous, and inconsistent responses to beta-blockers have been reported in some cases of infantile proliferative hemangiomas. On the basis of these clinical observations, we aimed to examine the β1 adrenergic receptor (β1-AR) protein expression distribution among different types of pediatric vascular anomalies. Methods Immunohistochemistry (IHC) was performed for β1-AR on 43 surgical specimens. Results We found positive β1-AR IHC staining in all intramuscular hemangiomas, capillary–lymphatic, lymphatic, venous, and combined malformations, and Masson’s tumor cases, as well as in 7 of 10 cases of proliferative infantile hemangiomas. Conclusions Our research demonstrates, for the first time, the degree of heterogeneous expression of β1-AR among pediatric vascular malformations. Our results support the need for β1-AR assessment in pediatric vascular anomalies to select cases with a robust response to β1-selective blockers. β1-AR assessment may have a strong impact on therapeutic refinement for pediatric vascular anomalies by selecting cases with a stronger response to beta-blockers.

show abstract

Section: Discussionmentioning

confidence: 85%

Expression of β1 adrenergic receptor in vascular anomalies in children

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The results showed significantly lower average blood pressure and heart rate in the atenolol group, with no instances of expansive hematoma observed, in contrast to several cases in the control group. A case series of oral atenolol administered to 46 infants with infantile hemangiomas resulted in complete involution in 61.8% and partial regression in 38.2%, while maintaining a favorable safety profile with mild transient side effects observed in 23.9% of cases (primarily diarrhea and mild sleep disturbance) [ 68 ]. Not all studies on the oral administration of beta-blockers were positive.…”

Section: Applications Of Beta-blockers In the Treatment Of Woundsmentioning

confidence: 99%

One Molecule, Many Faces: Repositioning Cardiovascular Agents for Advanced Wound Healing

Gościniak,

Stasiłowicz-Krzemień,

Michniak-Kohn

et al. 2024

Molecules

View full text Add to dashboard Cite

Chronic wound treatments pose a challenge for healthcare worldwide, particularly for the people in developed countries. Chronic wounds significantly impair quality of life, especially among the elderly. Current research is devoted to novel approaches to wound care by repositioning cardiovascular agents for topical wound treatment. The emerging field of medicinal products’ repurposing, which involves redirecting existing pharmaceuticals to new therapeutic uses, is a promising strategy. Recent studies suggest that medicinal products such as sartans, beta-blockers, and statins have unexplored potential, exhibiting multifaceted pharmacological properties that extend beyond their primary indications. The purpose of this review is to analyze the current state of knowledge on the repositioning of cardiovascular agents’ use and their molecular mechanisms in the context of wound healing.

show abstract

“…5 Oral propranolol requires vigilant monitoring to ensure significant adverse effects are not missed; a potential alternative is atenolol, which might be as effective and better tolerated but has less evidence for its application. 21,22 A meta-analysis has shown that propranolol has a clearance rate of 95% (complete or nearly complete resolution). 23 Where β-blockers are poorly tolerated, contraindicated or not effective, oral corticosteroids can be used and have a clearance rate of 43%.…”

Section: Managementmentioning

confidence: 99%